Download PDF
Semin Thromb Hemost 2010; 36(4): 404-418
DOI: 10.1055/s-0030-1254049
© Thieme Medical Publishers

Disseminated Intravascular Coagulation in Obstetric and Gynecologic Disorders

Martina Montagnana1 , Massimo Franchi1 , 2 , Elisa Danese1 , 2 , Francesca Gotsch1 , 2 , Gian Cesare Guidi1 , 2
  • 1Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy
  • 2Unità di Ostetricia, Dipartimento Materno ed Infantile, Università degli Studi di Verona, Verona, Italy
Further Information

Publication History

Publication Date:
07 July 2010 (online)

    Permissions and Reprints

ABSTRACT

Disseminated intravascular coagulation (DIC) is a syndrome characterized by a massive, widespread, and ongoing activation of the coagulation system, secondary to a variety of clinical conditions. Many obstetric complications, such as abruptio placentae, amniotic fluid embolism, endotoxin sepsis, retained dead fetus, post-hemorrhagic shock, hydatidiform mole, and gynecologic malignancies, might trigger DIC. In these gynecologic and obstetric settings, DIC is usually associated with high mortality and morbidity rates. No single laboratory test is sensitive or specific enough to diagnose DIC definitively, but it can be diagnosed by using a combination of multiple clinical and laboratory tests that reflect the pathophysiology of the syndrome. At present, the therapeutical approach to pregnancy- and gynecologic-related DIC comprises the specific and aggressive treatment of the underlying disease, eventually followed by a supportive blood product replacement therapy and restoration of physiological anticoagulant pathways. This article reviews the etiopathogenesis, clinical manifestations, laboratory diagnosis, and therapy of pregnancy- and gynecologic-related DIC.

KEYWORDS

Coagulation - disseminated intravascular coagulation - DIC - obstetrics - pregnancy

REFERENCES

  • 1 Matsuda T. Clinical aspects of DIC—disseminated intravascular coagulation.  Pol J Pharmacol. 1996;  48(1) 73-75
    PubMedGoogle Scholar
  • 2 Taylor Jr F B, Toh C H, Hoots W K, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86(5) 1327-1330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Levi M. Disseminated intravascular coagulation.  Crit Care Med. 2007;  35(9) 2191-2195
    CrossrefPubMedGoogle Scholar
  • 4 Letsky E A. Disseminated intravascular coagulation.  Best Pract Res Clin Obstet Gynaecol. 2001;  15(4) 623-644
    CrossrefPubMedGoogle Scholar
  • 5 Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.  Thromb J. 2006;  4 4
    CrossrefPubMedGoogle Scholar
  • 6 Franchini M. Haemostasis and pregnancy.  Thromb Haemost. 2006;  95(3) 401-413
    PubMedGoogle Scholar
  • 7 O'Riordan M N, Higgins J R. Haemostasis in normal and abnormal pregnancy.  Best Pract Res Clin Obstet Gynaecol. 2003;  17(3) 385-396
    CrossrefPubMedGoogle Scholar
  • 8 Bremme K A. Haemostatic changes in pregnancy.  Best Pract Res Clin Haematol. 2003;  16(2) 153-168
    CrossrefPubMedGoogle Scholar
  • 9 Sattar N, Greer I A, Rumley A et al.. A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy.  Thromb Haemost. 1999;  81(1) 71-75
    PubMedGoogle Scholar
  • 10 Stirling Y, Woolf L, North W RS, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy.  Thromb Haemost. 1984;  52(2) 176-182
    PubMedGoogle Scholar
  • 11 Dalaker K, Prydz H. The coagulation factor VII in pregnancy.  Br J Haematol. 1984;  56(2) 233-241
    CrossrefPubMedGoogle Scholar
  • 12 Østerud B, Bjørklid E. Sources of tissue factor.  Semin Thromb Hemost. 2006;  32(1) 11-23
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis.  Eur J Obstet Gynecol Reprod Biol. 1997;  73(1) 31-36
    CrossrefPubMedGoogle Scholar
  • 14 Collen D, de Cock F, Verstraete M. Quantitation of thrombin-antithrombin III complexes in human blood.  Eur J Clin Invest. 1977;  7(5) 407-411
    CrossrefPubMedGoogle Scholar
  • 15 Mahieu B, Jacobs N, Mahieu S et al.. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.  Blood Coagul Fibrinolysis. 2007;  18(7) 685-688
    CrossrefPubMedGoogle Scholar
  • 16 Oruç S, Saruç M, Koyuncu F M, Ozdemir E. Changes in the plasma activities of protein C and protein S during pregnancy.  Aust N Z J Obstet Gynaecol. 2000;  40(4) 448-450
    CrossrefPubMedGoogle Scholar
  • 17 Lindqvist P G, Svensson P J, Marsaál K, Grennert L, Luterkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy.  Thromb Haemost. 1999;  81(4) 532-537
    PubMedGoogle Scholar
  • 18 Lindqvist P G, Svensson P, Dahlbäck B. Activated protein C resistance—in the absence of factor V Leiden—and pregnancy.  J Thromb Haemost. 2006;  4(2) 361-366
    CrossrefPubMedGoogle Scholar
  • 19 Hellgren M. Hemostasis during normal pregnancy and puerperium.  Semin Thromb Hemost. 2003;  29(2) 125-130
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Robb A O, Mills N L, Din J N et al.. Acute endothelial tissue plasminogen activator release in pregnancy.  J Thromb Haemost. 2009;  7(1) 138-142
    CrossrefPubMedGoogle Scholar
  • 21 Astedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor.  Thromb Haemost. 1986;  56(1) 63-65
    PubMedGoogle Scholar
  • 22 Delorme M A, Burrows R F, Ofosu F A, Andrew M. Thrombin regulation in mother and fetus during pregnancy.  Semin Thromb Hemost. 1992;  18(1) 81-90
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Maruyama I, Bell C E, Majerus P W. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta.  J Cell Biol. 1985;  101(2) 363-371
    CrossrefPubMedGoogle Scholar
  • 24 Crawley J T, Gu J M, Ferrell G, Esmon C T. Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development.  Thromb Haemost. 2002;  88(2) 259-266
    PubMedGoogle Scholar
  • 25 Edstrom C S, Calhoun D A, Christensen R D. Expression of tissue factor pathway inhibitor in human fetal and placental tissues.  Early Hum Dev. 2000;  59(2) 77-84
    CrossrefPubMedGoogle Scholar
  • 26 Liu X H, Jiang Y M, Shi H, Yue X A, Wang Y F, Yang H. Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women.  Int J Gynaecol Obstet. 2009;  105(3) 240-243
    CrossrefPubMedGoogle Scholar
  • 27 Fay R A, Hughes A O, Farron N T. Platelets in pregnancy: hyperdestruction in pregnancy.  Obstet Gynecol. 1983;  61(2) 238-240
    PubMedGoogle Scholar
  • 28 Justin C, Taylor D J. Bleeding in late pregnancy. In: James DK, Steer PJ, Weiner CP, Gonik B High Risk Pregnancy. 2nd ed. Philadelphia, PA; WB Saunders 1999: 111-128
    PubMedGoogle Scholar
  • 29 Sher G, Statland B E. Abruptio placentae with coagulopathy: a rational basis for management.  Clin Obstet Gynecol. 1985;  28(1) 15-23
    CrossrefPubMedGoogle Scholar
  • 30 Hall D R. Abruptio placentae and disseminated intravascular coagulopathy.  Semin Perinatol. 2009;  33(3) 189-195
    CrossrefPubMedGoogle Scholar
  • 31 Krikun G, Huang S T, Schatz F, Salafia C, Stocco C, Lockwood C J. Thrombin activation of endometrial endothelial cells: a possible role in intrauterine growth restriction.  Thromb Haemost. 2007;  97(2) 245-253
    PubMedGoogle Scholar
  • 32 Kuczyński J, Uszyński W, Zekanowska E, Soszka T, Uszyński M. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the placenta and myometrium.  Eur J Obstet Gynecol Reprod Biol. 2002;  105(1) 15-19
    CrossrefPubMedGoogle Scholar
  • 33 Mahmoodian S. DIC and acute renal failure as a complication of abruptio placentae.  W V Med J. 1989;  85(12) 527-530
    PubMedGoogle Scholar
  • 34 Lain K Y, Roberts J M. Contemporary concepts of the pathogenesis and management of preeclampsia.  JAMA. 2002;  287(24) 3183-3186
    CrossrefPubMedGoogle Scholar
  • 35 Practice Bulletin ACOG .Diagnosis and Management of Preeclampsia and Eclampsia. Clinical Management Guidelines for Obstetrician-Gynecologists. Washington, DC; American College of Obstetricians and Gynecologists 2002 Number 33
    PubMedGoogle Scholar
  • 36 Rath W, Faridi A, Dudenhausen J W. HELLP syndrome.  J Perinat Med. 2000;  28(4) 249-260
    CrossrefPubMedGoogle Scholar
  • 37 Sibai B M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count.  Obstet Gynecol. 2004;  103(5 Pt 1) 981-991
    CrossrefPubMedGoogle Scholar
  • 38 Roberts J M, Lain K Y. Recent Insights into the pathogenesis of pre-eclampsia.  Placenta. 2002;  23(5) 359-372
    CrossrefPubMedGoogle Scholar
  • 39 Rinehart B K, Terrone D A, Lagoo-Deenadayalan S et al.. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia.  Am J Obstet Gynecol. 1999;  181(4) 915-920
    CrossrefPubMedGoogle Scholar
  • 40 Tanjung M T, Siddik H D, Hariman H, Koh S C. Coagulation and fibrinolysis in preeclampsia and neonates.  Clin Appl Thromb Hemost. 2005;  11(4) 467-473
    CrossrefPubMedGoogle Scholar
  • 41 Popek E J. Normal anatomy and histology of the placenta. In: Lewis SH, Perrin EZ Pathology of the Placenta. 2nd ed. Philadelphia, PA; Churchill Livingstone 1999: 49-88
    PubMedGoogle Scholar
  • 42 Griffin J H, Kojima K, Banka C L, Curtiss L K, Fernández J A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.  J Clin Invest. 1999;  103(2) 219-227
    CrossrefPubMedGoogle Scholar
  • 43 Thachil J, Toh C H. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management.  Blood Rev. 2009;  23(4) 167-176
    CrossrefPubMedGoogle Scholar
  • 44 van der Poll T, Büller H R, ten Cate H et al.. Activation of coagulation after administration of tumor necrosis factor to normal subjects.  N Engl J Med. 1990;  322(23) 1622-1627
    CrossrefPubMedGoogle Scholar
  • 45 Coughlin S R. Thrombin signalling and protease-activated receptors.  Nature. 2000;  407(6801) 258-264
    CrossrefPubMedGoogle Scholar
  • 46 Schjetlein R, Haugen G, Wisløff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation.  Acta Obstet Gynecol Scand. 1997;  76(6) 541-546
    CrossrefPubMedGoogle Scholar
  • 47 Perry Jr K G, Martin Jr J N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia.  Clin Obstet Gynecol. 1992;  35(2) 338-350
    PubMedGoogle Scholar
  • 48 Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert L J, Davidge S T. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia.  Hypertens Pregnancy. 2001;  20(2) 185-194
    CrossrefPubMedGoogle Scholar
  • 49 Clark S L, Hankins G DV, Dudley D A, Dildy G A, Porter T F. Amniotic fluid embolism: analysis of the national registry.  Am J Obstet Gynecol. 1995;  172(4 Pt 1) 1158-1167 discussion 1167-1169
    CrossrefPubMedGoogle Scholar
  • 50 Perozzi K J, Englert N C. Amniotic fluid embolism: an obstetric emergency.  Crit Care Nurse. 2004;  24(4) 54-61
    PubMedGoogle Scholar
  • 51 Phillips L L, Davidson Jr E C. Procoagulant properties of amniotic fluid.  Am J Obstet Gynecol. 1972;  113(7) 911-919
    PubMedGoogle Scholar
  • 52 Zhou J, Liu S, Ma M et al.. Procoagulant activity and phosphatidylserine of amniotic fluid cells.  Thromb Haemost. 2009;  101(5) 845-851
    PubMedGoogle Scholar
  • 53 Uszynski M. Amniotic fluid embolism: the complication of known pathomechanism but without pathogenetic therapy?.  Thromb Haemost. 2009;  101(5) 795-796
    PubMedGoogle Scholar
  • 54 Butler E E, Colón I, Druzin M L, Rose J. Postural equilibrium during pregnancy: decreased stability with an increased reliance on visual cues.  Am J Obstet Gynecol. 2006;  195(4) 1104-1108
    CrossrefPubMedGoogle Scholar
  • 55 Yaffe H, Hay-Am E, Sadovsky E. Thromboplastic activity of amniotic fluid in term and postmature gestations.  Obstet Gynecol. 1981;  57(4) 490-492
    PubMedGoogle Scholar
  • 56 Benson M D. A hypothesis regarding complement activation and amniotic fluid embolism.  Med Hypotheses. 2007;  68(5) 1019-1025
    CrossrefPubMedGoogle Scholar
  • 57 Gómez Ponce de León R, Wing D, Fiala C. Misoprostol for intrauterine fetal death.  Int J Gynaecol Obstet. 2007;  99(Suppl 2) S190-S193
    CrossrefPubMedGoogle Scholar
  • 58 Pollak L, Schiffer J, Leonov Y, Zaidenstein R. Acute subdural hematoma following disseminated intravascular coagulation associated with an obstetric catastrophe.  Isr J Med Sci. 1995;  31(8) 489-491
    PubMedGoogle Scholar
  • 59 Erez O, Gotsch F, Mazaki-Tovi S et al.. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.  J Matern Fetal Neonatal Med. 2009;  22(8) 672-687
    CrossrefPubMedGoogle Scholar
  • 60 van Gorp E C, Suharti C, ten Cate H et al.. Review: infectious diseases and coagulation disorders.  J Infect Dis. 1999;  180(1) 176-186
    CrossrefPubMedGoogle Scholar
  • 61 Rana A, Pradhan N, Gurung G, Singh M. Induced septic abortion: a major factor in maternal mortality and morbidity.  J Obstet Gynaecol Res. 2004;  30(1) 3-8
    CrossrefPubMedGoogle Scholar
  • 62 Thorp J A, Helfgott A W, King E A, King A A, Minyard A N. Maternal death after second-trimester genetic amniocentesis.  Obstet Gynecol. 2005;  105(5 Pt 2) 1213-1215
    CrossrefPubMedGoogle Scholar
  • 63 Hamoda H, Chamberlain P F. Clostridium welchii infection following amniocentesis: a case report and review of the literature.  Prenat Diagn. 2002;  22(9) 783-785
    CrossrefPubMedGoogle Scholar
  • 64 Plachouras N, Sotiriadis A, Dalkalitsis N, Kontostolis E, Xiropotamos N, Paraskevaidis E. Fulminant sepsis after invasive prenatal diagnosis.  Obstet Gynecol. 2004;  104(6) 1244-1247
    CrossrefPubMedGoogle Scholar
  • 65 Barela A I, Kleinman G E, Golditch I M, Menke D J, Hogge W A, Golbus M S. Septic shock with renal failure after chorionic villus sampling.  Am J Obstet Gynecol. 1986;  154(5) 1100-1102
    PubMedGoogle Scholar
  • 66 Rittirsch D, Flierl M A, Ward P A. Harmful molecular mechanisms in sepsis.  Nat Rev Immunol. 2008;  8(10) 776-787
    CrossrefPubMedGoogle Scholar
  • 67 Schouten M, Wiersinga W J, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis.  J Leukoc Biol. 2008;  83(3) 536-545
    CrossrefPubMedGoogle Scholar
  • 68 Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation.  Am J Hematol. 1997;  54(3) 219-224
    CrossrefPubMedGoogle Scholar
  • 69 Hack C E. Fibrinolysis in disseminated intravascular coagulation.  Semin Thromb Hemost. 2001;  27(6) 633-638
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Bick R L. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care.  Clin Appl Thromb Hemost. 2002;  8(1) 1-31
    CrossrefPubMedGoogle Scholar
  • 71 Hofmeyr G J, Mohlala B K. Hypovolaemic shock.  Best Pract Res Clin Obstet Gynaecol. 2001;  15 645-662
    CrossrefPubMedGoogle Scholar
  • 72 Purdie F R, Nieto J M, Summerson D J, Livermore W E. Rupture of the uterus with DIC.  Ann Emerg Med. 1983;  12(3) 174-176
    CrossrefPubMedGoogle Scholar
  • 73 Zimmerman L H. Causes and consequences of critical bleeding and mechanisms of blood coagulation.  Pharmacotherapy. 2007;  27(9 Pt 2) 45S-56S
    CrossrefPubMedGoogle Scholar
  • 74 Drife J. Management of primary postpartum haemorrhage.  Br J Obstet Gynaecol. 1997;  104(3) 275-277
    PubMedGoogle Scholar
  • 75 Haljamäe H. The pathophysiology of shock.  Acta Anaesthesiol Scand Suppl. 1993;  98 3-6
    PubMedGoogle Scholar
  • 76 Sherman L A. DIC in massive transfusion.  Prog Clin Biol Res. 1982;  108 171-189
    PubMedGoogle Scholar
  • 77 Linder M, Müller-Berghaus G, Lasch H G, Gagel C. Virus infection and blood coagulation.  Thromb Diath Haemorrh. 1970;  23(1) 1-11
    PubMedGoogle Scholar
  • 78 McKay D G, Margaretten W. Disseminated intravascular coagulation in virus diseases.  Arch Intern Med. 1967;  120(2) 129-152
    CrossrefPubMedGoogle Scholar
  • 79 Yücesoy G, Ozkan S O, Bodur H, Cakiroğlu Y, Calişkan E, Ozeren S. Acute fatty liver of pregnancy complicated with disseminated intravascular coagulation and haemorrhage: a case report.  Int J Clin Pract Suppl. 2005;  147(Suppl) 82-84
    PubMedGoogle Scholar
  • 80 Bick R L. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management.  Semin Thromb Hemost. 1978;  5(1) 1-26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Contrino J, Hair G, Kreutzer D L, Rickles F R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.  Nat Med. 1996;  2(2) 209-215
    CrossrefPubMedGoogle Scholar
  • 82 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost. 1999;  25(2) 173-182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells.  Blood. 1998;  92 143-151
    PubMedGoogle Scholar
  • 84 Donati M B. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice.  Thromb Haemost. 1995;  74(1) 278-281
    PubMedGoogle Scholar
  • 85 Semeraro N, Montemurro P, Conese M et al.. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies.  Int J Cancer. 1990;  45(2) 251-254
    CrossrefPubMedGoogle Scholar
  • 86 Levi M. Disseminated intravascular coagulation in cancer patients.  Best Pract Res Clin Haematol. 2009;  22(1) 129-136
    CrossrefPubMedGoogle Scholar
  • 87 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102(6) V215-V224
    CrossrefPubMedGoogle Scholar
  • 88 Tsakok F H, Koh S, Ilancheran A, Poh W K, Ratnam S S. Maternal death associated with hydatidiform molar pregnancy.  Int J Gynaecol Obstet. 1983;  21(6) 485-490
    CrossrefPubMedGoogle Scholar
  • 89 Egley C C, Simon L R, Haddox T. Hydatidiform mole and disseminated intravascular coagulation.  Am J Obstet Gynecol. 1975;  121(8) 1122
    PubMedGoogle Scholar
  • 90 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation.  Br J Haematol. 2009;  145(1) 24-33
    CrossrefPubMedGoogle Scholar
  • 91 Mant M J, King E G. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients.  Am J Med. 1979;  67(4) 557-563
    CrossrefPubMedGoogle Scholar
  • 92 Mant M J, Hirsh J, Pineo G F, Luke K H. Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII.  Br J Haematol. 1973;  24(6) 725-734
    CrossrefPubMedGoogle Scholar
  • 93 Deutsch H F, Gerarde H W. Biophysical studies of blood plasma proteins: effect of fibrinogen on prothrombin time.  J Biol Chem. 1946;  166 381
    PubMedGoogle Scholar
  • 94 Pati H P, Saraya A K, Charan V D, Sundaram K R, Sharma M C, Choudhary V P. Prognostic role of screening tests of haemostasis and underlying diseases in acute disseminated intra-vascular coagulation in adults.  Clin Lab Haematol. 1994;  16(1) 9-13
    CrossrefPubMedGoogle Scholar
  • 95 Bick R L. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response.  Semin Thromb Hemost. 1996;  22(1) 69-88
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Toh C H, Dennis M. Disseminated intravascular coagulation: old disease, new hope.  BMJ. 2003;  327(7421) 974-977
    CrossrefPubMedGoogle Scholar
  • 97 Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma.  Semin Thromb Hemost. 2008;  34(7) 604-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Toh C H, Giles A R. Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC).  Clin Lab Haematol. 2002;  24(6) 321-327
    CrossrefPubMedGoogle Scholar
  • 99 Bick R L. Disseminated intravascular coagulation: clinical/laboratory correlations.  Am J Clin Pathol. 1982;  77 244
    PubMedGoogle Scholar
  • 100 Ten Cate H. Trombocytopenia: one of the markers of disseminated intravascular coagulation.  Pathophysiol Haemost Thromb. 2003–2004;  33(5–6) 413-416
    CrossrefPubMedGoogle Scholar
  • 101 Spero J A, Lewis J H, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients.  Thromb Haemost. 1980;  43(1) 28-33
    PubMedGoogle Scholar
  • 102 Drews R E. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.  Clin Chest Med. 2003;  24(4) 607-622
    CrossrefPubMedGoogle Scholar
  • 103 Hong K H, Kim H K, Kim J E, Jung J S, Han K S, Cho H I. Prognostic value of immature platelet fraction and plasma thrombopoietin in disseminated intravascular coagulation.  Blood Coagul Fibrinolysis. 2009;  20(6) 409-414
    CrossrefPubMedGoogle Scholar
  • 104 Kim H K, Kim J E, Ham C K, Lee D S, Park S, Cho H I. Prognostic value of platelet indices as determined by ADVIA 120 in patients suspected of having disseminated intravascular coagulation.  Int J Lab Hematol. 2008;  30(2) 117-123
    CrossrefPubMedGoogle Scholar
  • 105 Labelle C A, Kitchens C S. Disseminated intravascular coagulation: treat the cause, not the lab values.  Cleve Clin J Med. 2005;  72(5) 377-378, 383–385, 390 passim
    CrossrefPubMedGoogle Scholar
  • 106 Kim H K, Lee D S, Kang S H, Kim J Q, Park S, Cho H I. Utility of the fibrinogen/C-reactive protein ratio for the diagnosis of disseminated intravascular coagulation.  Acta Haematol. 2007;  117(1) 34-39
    CrossrefPubMedGoogle Scholar
  • 107 Asakura H, Shiratori Y, Jokaji H et al.. Changes in plasma levels of prothrombin fragment F 1 + 2 in cases of disseminated intravascular coagulation.  Acta Haematol. 1993;  89(1) 22-25
    PubMedGoogle Scholar
  • 108 Takahashi H, Wada K, Niwano H, Shibata A. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation.  Blood Coagul Fibrinolysis. 1992;  3(6) 813-818
    CrossrefPubMedGoogle Scholar
  • 109 Teitel J M, Bauer K A, Lau H K, Rosenberg R D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex.  Blood. 1982;  59(5) 1086-1097
    PubMedGoogle Scholar
  • 110 Bick R L. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment.  Hematol Oncol Clin North Am. 2003;  17(1) 149-176
    CrossrefPubMedGoogle Scholar
  • 111 Rosenberg J S, Beeler D L, Rosenberg R D. Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin.  J Biol Chem. 1975;  250(5) 1607-1617
    PubMedGoogle Scholar
  • 112 Wada H, Minamikawa K, Wakita Y et al.. Hemostatic study before onset of disseminated intravascular coagulation.  Am J Hematol. 1993;  43 190-194
    CrossrefPubMedGoogle Scholar
  • 113 Okugawa Y, Wada H, Noda T et al.. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.  Am J Hematol. 2000;  65(3) 210-214
    CrossrefPubMedGoogle Scholar
  • 114 Kawasugi K, Simazu C, Noguchi M et al.. Increased thrombin generation capacity in septic patients with DIC.  J Thromb Haemost. 2007;  5(Suppl 2) P-T-236
    PubMedGoogle Scholar
  • 115 Hemker H C, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system.  Thromb Haemost. 2006;  96(5) 553-561
    Article in Thieme ConnectPubMedGoogle Scholar
  • 116 Seo J W, Kim H K, Kim J E, Park S, Cho H I. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.  Thromb Res. 2009;  123(4) 565-572
    CrossrefPubMedGoogle Scholar
  • 117 Exner T, Joseph J, Low J, Connor D, Ma D. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid.  Blood Coagul Fibrinolysis. 2003;  14(8) 773-779
    CrossrefPubMedGoogle Scholar
  • 118 Levi M, Ten Cate H. Disseminated intravascular coagulation.  N Engl J Med. 1999;  341(8) 586-592
    CrossrefPubMedGoogle Scholar
  • 119 Cadroy Y, Grandjean H, Pichon J et al.. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia.  Br J Obstet Gynaecol. 1993;  100(5) 416-420
    PubMedGoogle Scholar
  • 120 Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.  Am J Hematol. 1988;  28(3) 162-166
    CrossrefPubMedGoogle Scholar
  • 121 Shaper A G, Macintosh D M, Evans C M, Kyobe J. Fibrinolysis and plasminogen levels in pregnancy and the puerperium.  Lancet. 1965;  2(7415) 706-708
    PubMedGoogle Scholar
  • 122 Kruithof E K, Tran-Thang C, Gudinchet A et al.. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.  Blood. 1987;  69(2) 460-466
    PubMedGoogle Scholar
  • 123 Carr J M, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer.  Am J Clin Pathol. 1989;  91(3) 280-287
    PubMedGoogle Scholar
  • 124 Brenner B. Haemostatic changes in pregnancy.  Thromb Res. 2004;  114(5–6) 409-414
    CrossrefPubMedGoogle Scholar
  • 125 Francis C W, Marder V J. A molecular model of plasmic degradation of crosslinked fibrin.  Semin Thromb Hemost. 1982;  8(1) 25-35
    Article in Thieme ConnectPubMedGoogle Scholar
  • 126 Bick R L, Baker W F. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC).  Thromb Res. 1992;  65 785-790
    CrossrefPubMedGoogle Scholar
  • 127 Toh C H, Hoots W K. SSC on Disseminated Intravascular Coagulation of the ISTH . The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.  J Thromb Haemost. 2007;  5(3) 604-606
    CrossrefPubMedGoogle Scholar
  • 128 Nakahara K, Kazahaya Y, Shintani Y et al.. Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations.  Thromb Haemost. 2003;  89(5) 832-836
    PubMedGoogle Scholar
  • 129 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients.  Semin Thromb Hemost. 2008;  34(5) 459-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Levi M. Disseminated intravascular coagulation: what's new?.  Crit Care Clin. 2005;  21(3) 449-467
    CrossrefPubMedGoogle Scholar
  • 131 Esmon C T. The regulation of natural anticoagulant pathways.  Science. 1987;  235(4794) 1348-1352
    CrossrefPubMedGoogle Scholar
  • 132 Clark P, Brennand J, Conkie J A, McCall F, Greer I A, Walker I D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy.  Thromb Haemost. 1998;  79(6) 1166-1170
    PubMedGoogle Scholar
  • 133 Bick R L, Dukes M L, Wilson W L, Fekete L F. Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation.  Thromb Res. 1977;  10(5) 721-729
    CrossrefPubMedGoogle Scholar
  • 134 Holmes W E, Nelles L, Lijnen H R, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).  J Biol Chem. 1987;  262(4) 1659-1664
    PubMedGoogle Scholar
  • 135 Harpel P C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.  J Clin Invest. 1981;  68(1) 46-55
    CrossrefPubMedGoogle Scholar
  • 136 Levi M, Roem D, Kamp A M, de Boer J P, Hack C E, ten Cate J W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.  Thromb Haemost. 1993;  69(2) 141-146
    PubMedGoogle Scholar
  • 137 Mosad E, Elsayh K I, Eltayeb A A. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy.  Clin Appl Thromb Hemost. 2009;  , August 18 (Epub ahead of print)
    PubMedGoogle Scholar
  • 138 Wada H, Gabazza E C, Asakura H et al.. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC.  Am J Hematol. 2003;  74(1) 17-22
    CrossrefPubMedGoogle Scholar
  • 139 Lippi G, Guidi G C. Laboratory diagnostics in septic disseminated intravascular coagulation.  Eur Haematol. 2009;  3 19-24
    PubMedGoogle Scholar
  • 140 Bakhtiari K, Meijers J C, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation.  Crit Care Med. 2004;  32(12) 2416-2421
    CrossrefPubMedGoogle Scholar
  • 141 Gando S, Iba T, Eguchi Y Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria.  Crit Care Med. 2006;  34(3) 625-631
    CrossrefPubMedGoogle Scholar
  • 142 Moore J, Baldisseri M R. Amniotic fluid embolism.  Crit Care Med. 2005;  33(10, Suppl) S279-S285
    CrossrefPubMedGoogle Scholar
  • 143 Williams J, Mozurkewich E, Chilimigras J, Van De Ven C. Critical care in obstetrics: pregnancy-specific conditions.  Best Pract Res Clin Obstet Gynaecol. 2008;  22 825-846
    CrossrefPubMedGoogle Scholar
  • 144 von Dadelszen P, Menzies J, Gilgoff S et al.. Evidence-based management for preeclampsia.  Front Biosci. 2007;  12 2876-2889
    CrossrefPubMedGoogle Scholar
  • 145 Sibai B M. Magnesium sulfate prophylaxis in preeclampsia: evidence from randomized trials.  Clin Obstet Gynecol. 2005;  48(2) 478-488
    CrossrefPubMedGoogle Scholar
  • 146 Magann E F, Martin Jr J N. Twelve steps to optimal management of HELLP syndrome.  Clin Obstet Gynecol. 1999;  42(3) 532-550
    CrossrefPubMedGoogle Scholar
  • 147 Martin Jr J N, Rose C H, Briery C M. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child.  Am J Obstet Gynecol. 2006;  195(4) 914-934
    CrossrefPubMedGoogle Scholar
  • 148 Fonseca J E, Méndez F, Cataño C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial.  Am J Obstet Gynecol. 2005;  193(5) 1591-1598
    CrossrefPubMedGoogle Scholar
  • 149 Levi M. Current understanding of disseminated intravascular coagulation.  Br J Haematol. 2004;  124(5) 567-576
    CrossrefPubMedGoogle Scholar
  • 150 Carey M J, Rodgers G M. Disseminated intravascular coagulation: clinical and laboratory aspects.  Am J Hematol. 1998;  59(1) 65-73
    CrossrefPubMedGoogle Scholar
  • 151 Calder L, Hébert P C, Carter A O, Graham I D. Review of published recommendations and guidelines for the transfusion of allogeneic red blood cells and plasma.  Can Med Assoc J. 1997;  156(Suppl) S1-S8
    PubMedGoogle Scholar
  • 152 O'shaughnessy D F, Atterbury C, Bolton Maggs P British Committee for Standards in Haematology, Blood Transfusion Task Force et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.  Br J Haematol. 2004;  126(1) 11-28
    CrossrefPubMedGoogle Scholar
  • 153 Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists.  JAMA. 1994;  271(10) 777-781
    CrossrefPubMedGoogle Scholar
  • 154 Chowdhury P, Saayman A G, Paulus U, Findlay G P, Collins P W. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.  Br J Haematol. 2004;  125(1) 69-73
    CrossrefPubMedGoogle Scholar
  • 155 Samama C M. Prothrombin complex concentrates: a brief review.  Eur J Anaesthesiol. 2008;  25(10) 784-789
    CrossrefPubMedGoogle Scholar
  • 156 Josić D, Hoffer L, Buchacher A et al.. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity.  Thromb Res. 2000;  100(5) 433-441
    CrossrefPubMedGoogle Scholar
  • 157 United Kingdom Haemophilia Centre Doctors' Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.  Haemophilia. 2003;  9 1-23
    PubMedGoogle Scholar
  • 158 Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states.  Transfus Med. 2008;  18(3) 151-157
    CrossrefPubMedGoogle Scholar
  • 159 Fenger-Eriksen C, Lindberg-Larsen M, Christensen A Q, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.  Br J Anaesth. 2008;  101(6) 769-773
    CrossrefPubMedGoogle Scholar
  • 160 Kreuz W, Meili E, Peter-Salonen K et al.. Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency.  Transfus Apheresis Sci. 2005;  32 247-253
    CrossrefPubMedGoogle Scholar
  • 161 Manco-Johnson M J, Dimichele D, Castaman G Fibrinogen Concentrate Study group et al. Pharmacokinetics and safety of fibrinogen concentrate.  J Thromb Haemost. 2009;  7(12) 2064-2069
    CrossrefPubMedGoogle Scholar
  • 162 Pernerstorfer T, Hollenstein U, Hansen J et al.. Heparin blunts endotoxin-induced coagulation activation.  Circulation. 1999;  100(25) 2485-2490
    PubMedGoogle Scholar
  • 163 Feinstein D I. Treatment of disseminated intravascular coagulation.  Semin Thromb Hemost. 1988;  14(4) 351-362
    Article in Thieme ConnectPubMedGoogle Scholar
  • 164 Feinstein D I. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy.  Blood. 1982;  60(2) 284-287
    PubMedGoogle Scholar
  • 165 Howie P W, Prentice C R, Forbes C D. Failure of heparin therapy to affect the clinical course of severe pre-eclampsia.  Br J Obstet Gynaecol. 1975;  82(9) 711-717
    PubMedGoogle Scholar
  • 166 Goldhaber S Z. Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis.  Chest. 1998;  113(1) 5-7
    CrossrefPubMedGoogle Scholar
  • 167 Patel R, Cook D J, Meade M O Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study.  J Crit Care. 2005;  20(4) 341-347
    CrossrefPubMedGoogle Scholar
  • 168 Dörffler-Melly J, de Jonge E, Pont A C et al.. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors.  Lancet. 2002;  359(9309) 849-850
    CrossrefPubMedGoogle Scholar
  • 169 Rey E, Garneau P, David M et al.. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.  J Thromb Haemost. 2009;  7(1) 58-64
    CrossrefPubMedGoogle Scholar
  • 170 Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit.  Am J Hematol. 2004;  76(3) 225-229
    CrossrefPubMedGoogle Scholar
  • 171 Paternoster D, Stella A, Simioni P, Trovò S, Plebani P, Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia.  Int J Gynaecol Obstet. 1994;  47(3) 215-221
    CrossrefPubMedGoogle Scholar
  • 172 He S, Bremme K, Blombäck M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia.  Blood Coagul Fibrinolysis. 1997;  8(4) 232-238
    CrossrefPubMedGoogle Scholar
  • 173 Kobayashi A, Matsuda Y, Mitani M, Makino Y, Ohta H. Assessment of the usefulness of antithrombin-III in the management of disseminated intravascular coagulation in obstetrically ill patients.  Clin Appl Thromb Hemost. 2009;  , October 14 (Epub ahead of print)
    CrossrefPubMedGoogle Scholar
  • 174 Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y. Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial.  J Obstet Gynaecol Res. 2008;  34(1) 34-39
    PubMedGoogle Scholar
  • 175 Kobayashi T, Terao T, Ikenoue T et al.. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study.  Semin Thromb Hemost. 2003;  29(6) 645-652
    Article in Thieme ConnectPubMedGoogle Scholar
  • 176 Maki M, Kobayashi T, Terao T et al.. Antithrombin therapy for severe preeclampsia.  Thromb Haemost. 2000;  84 583-590
    PubMedGoogle Scholar
  • 177 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344(10) 699-709
    CrossrefPubMedGoogle Scholar
  • 178 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2(11) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 179 Bernard G R, Ely E W, Wright T J et al.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.  Crit Care Med. 2001;  29(11) 2051-2059
    CrossrefPubMedGoogle Scholar
  • 180 Kobayashi T, Terao T, Maki M, Ikenoue T. Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption.  Thromb Haemost. 1999;  82(4) 1363
    PubMedGoogle Scholar
  • 181 Sobieszczyk S, Breborowicz G, Platicanov V, Tanchev S, Kessler C M. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use.  Acta Obstet Gynecol Scand. 2006;  85 1239-1247
    CrossrefPubMedGoogle Scholar
  • 182 Segal S, Shemesh I Y, Blumental R et al.. The use of recombinant factor VIIa in severe postpartum hemorrhage.  Acta Obstet Gynecol Scand. 2004;  83(8) 771-772
    CrossrefPubMedGoogle Scholar
  • 183 Brice A, Hilbert U, Roger-Christoph S et al.. Recombinant activated factor VII as a life-saving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management. [in French].  Ann Fr Anesth Reanim. 2004;  23(11) 1084-1088
    PubMedGoogle Scholar
  • 184 Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage.  Br J Anaesth. 2005;  94(5) 592-595
    CrossrefPubMedGoogle Scholar
  • 185 Lewis N R, Brunker P, Lemire S J, Kaufman R M. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage.  Transfusion. 2009;  49(4) 689-695
    CrossrefPubMedGoogle Scholar
  • 186 Padmanabhan A, Schwartz J, Spitalnik S L. Transfusion therapy in postpartum hemorrhage.  Semin Perinatol. 2009;  33(2) 124-127
    CrossrefPubMedGoogle Scholar
  • 187 Clark A D, Gordon W C, Walker I D, Tait R C. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.  Vox Sang. 2004;  86(2) 120-124
    CrossrefPubMedGoogle Scholar
  • 188 Franchini M, Franchi M, Bergamini V, Salvagno G L, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.  Semin Thromb Hemost. 2008;  34(1) 104-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 189 Franchini M, Manzato F, Salvagno G L, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.  Blood Coagul Fibrinolysis. 2007;  18(7) 589-593
    CrossrefPubMedGoogle Scholar
  • 190 Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.  Aust N Z J Obstet Gynaecol. 2008;  48(1) 12-16
    CrossrefPubMedGoogle Scholar

Dr. Martina MontagnanaM.D. 

Sezione di Chimica Clinica Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi

P.le Scuro 10, 37134 – Verona, Italy

Email: martina.montagnana@med.lu.se